Logo St.Gallen Breast Cancer Conference

19th St.Gallen International Breast Cancer Conference 2025

Primary Therapy of Patients with Early Breast Cancer. Evidence, Controversies, Consensus

12 – 15 March 2025, Vienna / Austria

Logo 19th St. Gallen Breast Cancer Conference Vienna 2025
Logo St.Gallen Breast Cancer Conference

19th St.Gallen International
Breast Cancer Conference 2025

Primary Therapy of Patients with Early Breast Cancer. Evidence, Controversies, Consensus

12 – 15 March 2025, Vienna / Austria

Logo 19th St.Gallen Breast Cancer Conference 2025

Detailed Scientific Programme

The theme of the 19th St.Gallen International Breast Cancer Conference is “Primary Therapy of Patients with Early Breast Cancer. Evidence, Controversies, Consensus. Individualizing therapy for patients with early-stage breast cancer: tailored local and systemic treatment”.

Programme as of August 2024.

Wednesday, 12 March  2025

The SGBCC Academy “Meet the Expert” Sessions allow virtual and on site participants to directly ask their questions to panelists of the St.Gallen Consensus and discuss the most pressing issues in client care faced by physicians around the world.

The panelists featured in the “Meet the Expert” Sessions will be announced in autumn 2024.

The SGBCC Academy “Meet the Expert” Sessions allow virtual and on site participants to directly ask their questions to panelists of the St.Gallen Consensus and discuss the most pressing issues in client care faced by physicians around the world.

The panelists featured in the “Meet the Expert” Sessions will be announced in autumn 2024.

Welcome on behalf of St.Gallen Oncology Conferences (SONK) and on behalf of the International Breast Cancer Study Group (IBCSG)
Beat Thuerlimann (Switzerland)

Welcome on behalf of the Austrian Breast Cancer Study Group (ABCSG), Medical University of Vienna, and co-operating partners from all over the world
Michael Gnant (Austria)

What to expect from SGBCC 2025
Sibylle Loibl (Germany)

Introduction of the Hans-Joerg Senn Memorial Lecture – handing over the St.Gallen Breast Cancer Award 2025
Walter Weber (Switzerland)

The Hansjoerg Senn Memorial Lecture 2025
My Personal Experience: Changing Surgery for Breast Cancer

Armando Giuliano (USA)

Closing
Giuseppe Curigliano (Italy)

Chairs: Giuseppe Curigliano, Hal Burstein

Breakthroughs and innovation in advanced disease – arriving in the curable setting soon?
Giuseppe Curigliano (Italy)

Novel endocrine agents – how to use and not abuse them in early breast cancer
Fabrice Andre (France)

New anti-HER2 approaches – moving up to the (neo)adjuvant setting?
Javier Cortes (Spain)

ADCs: new wonder drugs for early HR+ and TN breast cancer?
Sara Tolaney (United States of America)

Chairs: Sherene Loi / Nick Turner / Wolfgang Janni

The technology of detecting ctDNA: exuberance, and caution
Nick Turner (United Kingdom)

Clinical Utility of liquid biopsy for screening and MRD detection
Francois-Clement Bidard (France)

Perspectives – Adapting clinical trials to include ctDNA: what should be the endpoint?
Wolfgang Janni (Germany)

Discussion Moderator: Sherene Loi

Chairs: Martine Piccart / Carsten Denkert / Binghe Xu

20th Anniversary of adjuvant trastuzumab: reflections on a breakthrough moment
Martine Piccart (Belgium)

HER2 testing: Where we are 20 years later?
Carsten Denkert (Germany)

Risk adapted neoadjuvant and adjuvant therapy for HER2+ eBC
Nadia Harbeck (Germany)

Management of residual disease HER2-positive eBC
Komal Javheri (United States of America)

Discussion Moderator: Nadia Harbeck

Thursday, 13 March  2025

Chairs: David Cameron / Jens Huober / Shigehira Saji (invited)

When can we safely withhold radiotherapy and even surgery?
Charlotte Coles (United Kingdom)

Which older patients truly need chemotherapy?
Hans Wildiers (Belgium)

Pyrrhic victory? Are newer approaches causing more harm than good?
Mafalda Oliveira (Spain)

Discussion Moderator: David Cameron

Chairs: Walter Weber / Zhimin Shao / Monica Morrow

Why should we prevent mastectomies?
Jana de Boniface (Sweden)

Tailoring radiotherapy: Partial breast and hypofractionation, DCIS and molecular markers
Daniela Kauer-Dorner (Austria)

Breast surgery after neoadjuvant systemic treatment
Viviana Galimberti (Italy)

Breast reconstruction and quality of life
Christine Solbach (Germany)

Discussion Moderator: Jana de Boniface

In collaboration with the Chinese Society of Clinical Oncology (CSCO)

Experts from China will present key trials on breast cancer.

Details of the industry sponsored sessions will be published in January 2025.

The SGBCC Academy “Meet the Expert” Sessions allow virtual and on site participants to directly ask their questions to panelists of the St.Gallen Consensus and discuss the most pressing issues in client care faced by physicians around the world.

The panelists featured in the “Meet the Expert” Sessions will be announced in autumn 2024.

Chair: Walter Weber

For: Shelley Potter, Orit Kaidar-Person
Against: Monica Morrow, Philip Poortmans

Chairs: Hal Burstein / Michael Gnant / Meteb Al-Foheidi

Crawling towards cure – small steps of clinical benefit in HR+ (De-escalation, combination, new drugs? SERDs?)
David Cameron (United Kingdom)

Which ER+ tumors still require chemotherapy?
Kevin Kalinski (United States of America)

The long and winding road of individualized endocrine therapy in premenopausal women
Prudence Francis (Australia)

How long is long enough? Duration of endocrine therapy in view of locoregional treatment de-escalation
Terry Mamounas (United States of America)

Lobular breast cancer: unique approaches?
Marie-Jeanne Vrancken-Peeters (The Netherlands)

Multi-omic subtyping and precision-guided therapy of luminal breast cancer
Zhi-Ming Shao (China)

Which tumors warrant adjuvant CDK4/6 inhibitor therapy?
Angela deMichele (United States of America)

Which ER+ cancers will warrant immunotherapy approaches?
Marleen Kok (The Netherlands)

Discussion Moderator: Harold Burstein

Chairs: Fabrice Andre / Nadia Harbeck / Jacob Kather

What is the role of AI in breast pathology?
Jakob Kather (Germany)

What is the role of AI in planning radiation therapy?
Gerd Fastner (Austria)

Discussion Moderator: Jacob Kather

Presentation of the SGBCC 2025 Poster Awards for the 5 best abstract submissions to the conference.

The awardees will also present their works in a dedicated e-poster session on Friday, 14 March, from 11:00 – 11:30.

Chairs: Isabel Rubio / Bahadir Gulluoglu / Eriko Tokunaga (invited)

Where does PET imaging belong in initial staging?
Isabel Rubio (Spain)

What is the role of MRI in the initial presurgical work up?
Bahadir Gulluoglu (Turkey)

Most cancers (lung, colorectal, ovarian, prostate, leukemia, lymphoma) have surveillance studies: is it time to re-think our approach in breast cancer?
Jens Huober (Switzerland)

Discussion Moderator: Bahadir Gulluoglu

Details of the industry sponsored sessions will be published in January 2025.

Friday, 14 March  2025

Chairs: Christian Singer / Andrew Tutt / Sara Brucker

Genetic testing: risk-adapted approaches, or make it universal?
Shani Paluch-Shimon (ISR)

Risk reducing surgery: are nerve- or nipple-sparing techniques appropriate in mutation carriers?
Judy Boughey (United States of America)

Alternatives to risk reducing surgery – Intense surveillance or preventive therapies
Christian Singer (Austria)

What do we actually achieve with mastectomy in terms of outcome?
Kelly Metcalfe (Canada)

Discussion Moderator: Andrew Tutt

Chairs: Judy Boughey / Philip Poortmans / Chiun-Sheng Huang

Who can avoid upfront sentinel node and axillary surgery in node-negative and node-positive presentations
Cicero Urban (Brazil)

Axillary surgery in inflammatory breast cancer, local recurrence, or stage IV cancer
Maria Joao Cardoso (Portugal)

Axillary surgery after neoadjuvant chemotherapy
Walter Weber (Switzerland)

Nodal irradiation after neoadjuvant chemotherapy
Anusheel Munchi (India)

Discussion Moderator: Maria Joao Cardoso

The SGBCC poster award winners 2025 will present their work in short oral presentations at the e-poster terminals on level 1.

The SGBCC Academy “Meet the Expert” Sessions allow virtual and on site participants to directly ask their questions to panelists of the St.Gallen Consensus and discuss the most pressing issues in client care faced by physicians around the world.

The panelists featured in the “Meet the Expert” Sessions will be announced in autumn 2024.

Details of the industry sponsored sessions will be published in January 2025.

Chairs: Meredith Regan / Sara Tolaney

Strenghts and limitations of clinical trial design
Meredith Regan (United States of America)

Meaningful Measures – the clinicians perspective [who chooses clinical trial populations – only industry?]
David Cameron (United Kingdom)

Regulatory perspective – overextrapolating high risk derived data to average risk populations
Francesco Pignatti (European Medicines Agency)

Patient perspective – what do WE really need?
Tanja Spanic (Slovenia)

Discussion Moderator: Meredith Regan

2024 Clinical research highlights for early and late breast cancer
Virginia Kaklamani (United States of America)

Chair: Beat Thuerlimann

For: Catherine Kelly, Virginia Kaklamani
Against: Stephen Chia, Barbara Pistilli

Chairs: Prudence Francis / Jiang Zefei / Heba Gamal

Breast Cancer during pregnancy
Cristina Saura (Spain)

Fertility preservation and pregnancy after breast cancer
Matteo Lambertini (Italy)

Sexual health in breast cancer survivors
Laura Michel (Germany)

Addressing long-term toxicities from breast cancer treatments and evidence based approaches for healthy living in Breast Cancer
Cynthia Villarreal-Garza (Mexico)

Discussion Moderator: Prudence Francis (invited)

Chairs: Sibylle Loibl / Lisa Carey / Virginia Kaklamani

How much immunotherapy is enough?
Sherene Loi (Australia)

Quantifying residual disease, and understanding its biology and clinical implications
Fraser Symmans (United States of America)

Adjuvant therapy after pCR; adjuvant therapy with residual cancer
Lisa Carey (United States of America)

Does everyone with TNBC need chemotherapy? Which cancers – by stage or biology – do not?
Hope Rugo (United States of America)

Beyond PARP & BRCA: Next generation approaches to HRD
Andrew Tutt (United Kingdom)

Have we all become immunooncologists – long term side effects and how to handle them
Shaheena Dawood (United Arab Emirates)

Discussion Moderator: Hope Rugo

Details of the industry sponsored sessions will be published in January 2025.

Saturday, 15 March  2025

Moderator: Hal Burstein
Chairs: Giuseppe Curigliano, Michael Gnant, Sibylle Loibl

The members of the 2025 St.Gallen International Consensus Panel can be found here.

Kindly note that the SGBCC Academy “Meet the Expert” Sessions as well as the Voice of China Session will take place in break out rooms. All other sessions will take place in the plenary hall A.

Important Dates

Mark your calender to not miss any of our key dates and deadlines for your attendance and abstract submission to SGBCC 2025!